Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences (Nasdaq: TLSA) closed an oversubscribed registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising gross proceeds of approximately $8.8 million. Each share issued includes a warrant exercisable at $1.50 through July 16, 2026, which could yield up to ~$10.56 million in additional gross proceeds if fully exercised.
The offering was conducted without an underwriter and was subscribed by senior management and existing shareholders, including CEO Ivor Elrifi who bought 2,400,000 shares and increased his total to 2,757,848 shares, and Executive Chairman Gabriele Cerrone who bought 1,600,000 shares raising his total to 44,974,830 shares. Proceeds are intended to complete Phase 2 na-SPMS and MSA trials and deliver topline data readouts.
Tiziana Life Sciences (Nasdaq: TLSA) priced a registered direct offering of 6,400,000 ordinary shares at $1.25 per share, expected to raise approximately $8.0 million in gross proceeds before expenses. Each share purchased includes a warrant to buy one ordinary share at $1.50 exercisable through July 16, 2026, potentially generating up to an additional $9.6 million. The Offering, conducted without an underwriter and expected to close on January 16, 2026, was led by CEO Ivor Elrifi and included a purchase by Executive Chairman Gabriele Cerrone. Proceeds are intended to fund completion of the company’s Phase 2 na-SPMS and MSA clinical trials and topline data readouts.
Tiziana Life Sciences (NASDAQ: TLSA) said CEO Ivor Elrifi will present at the 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 at 2:00 PM PT at the Marines' Memorial Club in San Francisco during J.P. Morgan Healthcare Conference Week. Senior management will attend and be available for one-on-one investor and partner meetings.
The presentation will highlight the company's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody intended to modulate the immune system and reduce microglial activation in neurodegenerative and neuroinflammatory conditions, including non-active secondary progressive multiple sclerosis.
Tiziana (NASDAQ: TLSA) submitted its seventh annual Development Safety Update Report to the FDA covering Sept 21, 2024–Sept 2, 2025, reporting a cumulative 37.4 patient-years of intranasal foralumab exposure with no drug-related serious adverse events.
Key exposures: 14 naSPMS patients in Expanded Access (50 µg dose) contributed 30.7 patient-years; the TILS-021 randomized trial plus TILS-022 extension added ~5.2 patient-years; one AD patient added 0.5 patient-years. No new risks or safety actions were identified and nasal delivery showed improved tolerability versus prior IV foralumab reports. The company noted an FDA Dec 23, 2025 complete response letter denying approval of Sanofi’s tolebrutinib for nrSPMS and said its Phase 2 naSPMS readout is expected in 2026.
Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone purchased 97,687 common shares on Dec. 19, 2025.
After the purchase his total holding is 43,374,830 common shares, representing 36.08% of issued share capital.
Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone will ring the Nasdaq Closing Bell in Times Square on December 17, 2025 from 3:45 PM to 4:15 PM ET. The ceremony celebrates the company's progress advancing intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered nasally to target neurodegenerative and inflammatory diseases including multiple sclerosis, Alzheimer's disease, and ALS.
The company noted recent pipeline progress, including dosing the first patient in its Phase 2 Alzheimer's trial, and provided livestream links for the event.
Tiziana Life Sciences (Nasdaq: TLSA) announced that the first patient was dosed on December 17, 2025 in its randomized, placebo-controlled Phase 2 trial of intranasal foralumab for early Alzheimer’s disease.
The trial will evaluate foralumab as monotherapy and combined with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab, and is supported by TSPO-PET imaging data showing persistent microglial activation after amyloid reduction. The program tests an immunomodulatory approach targeting residual neuroinflammation with intranasal anti-CD3 foralumab; enrollment will continue and clinical outcomes are pending.
Tiziana Life Sciences (Nasdaq: TLSA) announced on December 15, 2025 that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of Tiziana common stock in the open market.
Following this transaction, the CEO's total purchased shares amount to 357,848. The purchase was executed on the open market and reflects an insider buy by the company's chief executive.
Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 15, 2025 that it has withdrawn its proposed public offering of common shares. The company said the withdrawal was made due to market conditions. The release also states that it does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction prior to required registration or qualification.
Tiziana Life Sciences (Nasdaq: TLSA) announced on Dec 12, 2025 that enrolment has begun in its Phase 2 randomized, placebo-controlled early Alzheimer’s trial and the company expects to dose the first patient next week. The study will test intranasal foralumab as monotherapy and combined with FDA-approved anti-amyloid therapies lecanemab or donanemab.
Baseline cognitive testing, fluid biomarkers and TSPO-PET imaging were completed in initial participants; new TSPO-PET evidence showed persistent, widespread microglial activation in an Alzheimer’s patient despite treatment with lecanemab, supporting the trial rationale to target residual neuroinflammation.